The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Symptom assessment in patients with JAK inhibitor naïve and JAK inhibitor failed myelofibrosis.
 
Yun Su
Employment - Bristol-Myers Squibb; Pfizer
Stock and Other Ownership Interests - Bristol-Myers Squibb; Pfizer
 
Adrian Woolfson
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Josef T. Prchal
No Relationships to Disclose
 
Kathleen Wyant Turnbull
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Claire N. Harrison
Honoraria - Baxalta; CTI; Novartis; Sanofi; Shire
Consulting or Advisory Role - Baxalta; CTI; Gilead Sciences
Speakers' Bureau - Baxalta; CTI; Gilead Sciences; Incyte; Novartis
Research Funding - CTI (Inst); Gilead Sciences (Inst); Novartis (Inst)
 
Elias Jabbour
Consulting or Advisory Role - Amgen; ARIAD; Pfizer
Research Funding - Amgen; ARIAD; Novartis; Pfizer
 
Robyn Marie Scherber
No Relationships to Disclose
 
Alan Shields
Consulting or Advisory Role - Adelphi (Inst)
Research Funding - Adelphi (Inst)
 
Meaghan Krohe
Employment - Adelphi
Research Funding - Adelphi; Adelphi (Inst)
 
Funke Ojo
Employment - Adelphi
 
Farrah Pompilus
Employment - Adelphi
 
Ruben A. Mesa
Honoraria - AOP Orphan Pharmaceuticals; Novartis; shire
Consulting or Advisory Role - Baxalta; Galena Biopharma; Incyte; Novartis
Research Funding - Celgene (Inst); CTI (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); NS Pharma (Inst); Pfizer (Inst); Pharmaessentia (Inst); Promedior (Inst)
Travel, Accommodations, Expenses - AOP Orphan Pharmaceuticals; Incyte; Novartis